Olodaterol is a long-acting beta2-adrenergic agonist used in the management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.
- Mechanism
- Curator reviewed
Olodaterol is a long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles.
- Primary indication
- Olodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.Curator reviewed · 2 structured indications
- Formula / weight
- C21H26N2O5 · 386.448 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2014
- Code names
- BI-1744
- Brand names
Resolves to
COUYJEVMBVSIHV-SFHVURJKSA-NSMILESCOC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Olodaterol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account